As a consequence of mediator release upon MRGPRX2-mediated degranulation, symptoms that are very similar to type I allergic reactions can develop and are therefore sometimes called “pseudo-allergic” reactions [4,17]. This evidence concerns the gene MRGPRX2 and allergic disease.